Cargando…

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML

SIMPLE SUMMARY: About 50% of adults with chronic myeloid leukemia (CML) in sustained deep molecular response (DMR) to tyrosine kinase inhibitors (TKI) could discontinue the treatment permanently without molecular relapse. Recommendations regarding discontinuation apply only for adults because childh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Millot, Frédéric, Suttorp, Meinolf, Ragot, Stéphanie, Leverger, Guy, Dalle, Jean-Hugues, Thomas, Caroline, Cheikh, Nathalie, Nelken, Brigitte, Poirée, Marilyne, Plat, Geneviève, Versluys, Birgitta, Lausen, Birgitte, Borisevich, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392145/ https://www.ncbi.nlm.nih.gov/pubmed/34439257 http://dx.doi.org/10.3390/cancers13164102

Ejemplares similares

Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia
por: Suttorp, Meinolf, et al.
Publicado: (2020)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
por: Sembill, Stephanie, et al.
Publicado: (2023)

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment
por: Bettoni da Cunha-Riehm, Claudia, et al.
Publicado: (2020)

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment
por: Jaeger, Bernadette Anna Sophia, et al.
Publicado: (2012)

Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia
por: Suttorp, Meinolf, et al.
Publicado: (2021)

Priapism at Diagnosis of Pediatric Chronic Myeloid Leukemia: Data Derived from a Large Cohort of Children and Teenagers and a Narrative Review on Priapism Management
por: Suttorp, Meinolf, et al.
Publicado: (2023)

Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats
por: Tauer, Josephine T., et al.
Publicado: (2015)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
por: McLigeyo, Angela, et al.
Publicado: (2020)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
por: Enriquez, Virginia, et al.
Publicado: (2007)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
por: Li, Hui, et al.
Publicado: (2016)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
por: Millot, Frédéric, et al.
Publicado: (2017)

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
por: Bernardi, Simona, et al.
Publicado: (2019)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
por: Mohajeri, Ehsan, et al.
Publicado: (2015)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3
por: Wang, Houcai, et al.
Publicado: (2016)

Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib
por: Jin, Yanli, et al.
Publicado: (2016)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
por: Hamza, Marwa S, et al.
Publicado: (2022)

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
por: Aceves-Luquero, Clara I., et al.
Publicado: (2009)

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2011)

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target
por: Toman, O., et al.
Publicado: (2016)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells
por: Zeng, Chengwu, et al.
Publicado: (2018)

CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML
por: Zhong, An-Ni, et al.
Publicado: (2021)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
por: Cerveira, Nuno, et al.
Publicado: (2018)

Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2014)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q5h9dknd0s4dmqdarij72t7ke4